The Neural Stem Cell Institute (NSCI) in Rensselaer, NY, focuses on advancing regenerative stem cell therapies aimed at treating various diseases affecting the central nervous system (CNS), including Alzheimer's, Parkinson's, and spinal cord injuries. A key area of their research involves the development of intracellular antibody therapies designed to target and eliminate aggregated proteins associated with tauopathies, which are linked to neurodegenerative diseases. Additionally, NSCI is dedicated to promoting the self-repair capabilities of the nervous system by activating dormant stem cells within the adult CNS, thereby facilitating repair and regeneration processes.

NSCI also operates the NeuraCell Core Facility, which provides essential stem cell resources and services to support scientific research and collaboration. Their innovative approach includes creating "Disease in a Dish" models using patient-derived stem cells to study degenerative diseases, allowing for better understanding and potential treatment strategies. Notably, NSCI researchers have identified a new type of stem cell, the Retinal Pigment Epithelial Stem Cell, which holds promise for cell replacement therapies and drug discovery aimed at treating blinding disorders. Through these initiatives, NSCI is at the forefront of stem cell research, contributing significantly to the field of regenerative medicine.

United States

Neural Stem Cell Institute is a regenerative medicine company that focuses on developing stem cell therapies for diseases of the nervous system.

Neural Stem Cell Institute, Rensselaer NY

Company Details